景嘉微(300474.SZ):子公司簽訂2.57億元合同
格隆匯 1 月 22日丨景嘉微(300474.SZ)公佈,公司全資子公司長沙景美集成電路設計有限公司(“景美”)於2021年1月22日與某公司簽訂了《採購合同》。此次合同標的:芯片委託製造,合同金額為2.57億元。
截至公吿披露日,公司及景美連續十二個月內與某公司簽訂多份日常經營性合同,合同金額累計達4.58億元,合同累計金額超過公司2019年度經審計主營業務收入的50%。
此次合同主要內容為芯片委託製造,購買晶圓等材料,公司主要基於對圖形顯控領域通用市場的產品備貨,上述合同的實施預計未來對公司產品在通用市場發展產生較為積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.